- Home
- MBC vs SLS Comparison
MBC vs SLS Comparison
Compare MBC & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBC | SLS |
|---|---|---|
| Founded | 1954 | 2012 |
| Country | United States | United States |
| Employees | 12000 | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 902.3M | 924.5M |
| IPO Year | 2022 | 2007 |
Fundamental Metrics
Financial Performance| Metric | MBC | SLS |
|---|---|---|
| Price | $7.10 | $8.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $15.00 | $10.00 |
| AVG Volume (30 Days) | 2.7M | ★ 6.1M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,734,700,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.55 | $110.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1.27 | N/A |
| 52 Week Low | $6.61 | $1.39 |
| 52 Week High | $14.22 | $7.80 |
Technical Indicators
Market Signals| Indicator | MBC | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 35.53 | 81.20 |
| Support Level | N/A | $3.55 |
| Resistance Level | $13.29 | N/A |
| Average True Range (ATR) | 0.41 | 0.52 |
| MACD | -0.10 | 0.36 |
| Stochastic Oscillator | 19.80 | 96.73 |
Price Performance
Historical ComparisonAbout MBC MasterBrand Inc.
MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers and builders.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.